Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
All articles — 32677 total
Baker Hughes has dropped another 5.4% this week to $55.50, extending a painful month that has now erased 13% — and the C-suite selling flagged in last week's note looks increasingly well-timed. The insider angle has…
Charter Communications heads into Q2 earnings season with a fractured setup: short sellers are trimming positions after a bruising spring, but the stock is still one of the most heavily shorted names in US cable, and…
JPSE — the JPMorgan Diversified Return U.S. Small Cap Equity ETF — enters July with a quiet but notable shift in its lending market, even as the underlying price trend remains constructive. The standout this week is…
Alcoa ends June with a worsening picture: the stock dropped another 5% on the week to $52.14, shorts are rebuilding at their fastest pace in months, and Q1 earnings in two weeks offer the next real test of whether the…
CRISPR Therapeutics heads into the second half of 2026 carrying one of the most charged short-side setups in biotech — short interest has jumped 20% in a single week while the stock trails its gene-editing peers by a…
FB Financial Corporation heads into its July 13 earnings report with short sellers quietly rebuilding positions while the analyst community moves in the opposite direction. The standout tension this week is timing.…
First Hawaiian heads into its July 24 earnings report having outrun most of its regional bank peers, while the Street remains firmly in hold-or-sell territory — a tension that sharpens as the stock has now exceeded the…
CRVS enters July with a striking contradiction at its core: the stock has rallied 18% in a week and 20% over the past month to close at $14.94, yet short sellers have not retreated — they have added to positions. Short…
BeOne Medicines enters July with short sellers voting heavily with their feet — and the borrow market confirming there's almost no conviction left on the bearish side. Short interest has collapsed over the past month,…
Altimmune enters July with one of the most heavily shorted positions in small-cap biotech, even as the stock edges higher and insiders continue to put their own money in. Short interest is the defining story here, and…
SPCX at $170.86 is a stock with a $190 bull target, a $115 bear target, and a Nasdaq 100 rebalance landing in two days — the Street's first week of formal coverage has produced no consensus whatsoever. The analyst…
HUBB heads into its July 28 earnings date with shorts quietly rebuilding, borrowing costs climbing, and the stock trading near all-time highs — a combination that makes the setup worth watching. Short interest has been…
Ferrari heads into the final trading day of June with a rare combination: a 7.5% weekly gain while virtually every close peer finished in the red. That divergence is the story. Porsche fell 6.3% on the week. Volkswagen…
LivaNova heads into its July 29 earnings date with short sellers quietly adding pressure after a strong month for the stock. The most notable tension this week is the divergence between price and positioning. LIVN…
XLRE closes out the first half of 2026 with a fresh tension: short interest has nudged back up over the past week even as the borrow market continues to loosen — a split that is worth watching as the fund slips back…
Chemours enters July with short sellers adding pressure and the Street trimming targets, even as the stock stages a modest recovery from last week's selloff. The most notable development this week is that short…
ABIVAX's ABVX stock exploded 39% on June 30, its biggest single-session move in months, yet the lending market tells a story of shorts who aren't backing down. The catalyst appears to be continued momentum around the…
Glaukos Corporation enters the final stretch of Q2 with a sharp and unusual divergence: short sellers have rebuilt positions aggressively over the past month, yet the options market just flipped to its most bullish…
BRSL enters the final stretch before its July 28 earnings with a notable shift in the analyst narrative — a fresh Deutsche Bank buy initiation arriving just as the extreme options defensiveness flagged last week has…
S32 heads into its July 20 production report carrying its worst monthly loss in recent memory, with the stock down 19% over the past month to AUD 3.90, while most of its peer group has also been under heavy selling…
